Skip to main content

Alemtuzumab Dosage

Medically reviewed by Drugs.com. Last updated on Aug 22, 2022.

Applies to the following strengths: 10 mg/mL; 30 mg/mL

Usual Adult Dose for Multiple Sclerosis

LEMTRADA(R) 10 mg/mL:


Comments:

Use: For relapsing forms of multiple sclerosis (MS) including relapsing-remitting disease and active secondary progressive disease; because of its safety profile, use should be reserved for patients who have had an inadequate response to 2 or more drugs for MS; not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile

Usual Adult Dose for Chronic Lymphocytic Leukemia

CAMPATH (R) 30 mg/mL:
Escalate dosing over 3 to 7 days at initiation of treatment or if dosing is held 7 days or more:
ESCALATION STRATEGY: 3 mg IV over 2 hours daily until infusion reactions are Grade 2 or less, then 10 mg IV over 2 hours daily until infusion reactions are Grade 2 or less, then 30 mg/day IV over 2 hours 3 times a week on alternate days (e.g., Mon/Wed/Fri).
Duration of therapy: 12 weeks (including dose escalation)

Comments:


Use: As a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL)

Usual Pediatric Dose for Multiple Sclerosis

17 years and older:
LEMTRADA(R) 10 mg/mL:


Comments:

Use: For relapsing forms of multiple sclerosis (MS) including relapsing-remitting disease and active secondary progressive disease; because of its safety profile, use should be reserved for patients who have had an inadequate response to 2 or more drugs for MS; not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

CAMPATH (R):
DOSE MODIFICATIONS FOR B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL):

DOSE MODIFICATION FOR NEUTROPENIA OR THROMBOCYTOPENIA:
ANC LESS THAN 250 PER MICROLITER AND/OR PLATELET COUNT LESS THAN OR EQUAL TO 25,000 PER MICROLITER:
GREATER THAN OR EQUAL TO 50% DECREASE FROM BASELINE IN PATIENTS INITIATING THERAPY WITH A BASELINE ANC LESS THAN OR EQUAL TO 250 PER MICROLITER AND/OR A BASELINE PLATELET COUNT LESS THAN OR EQUAL TO 25,000 PER MICROLITER:

Precautions

The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for Lemtrada (R). It includes a communication plan, elements to assure safe use, and an implementation system. For additional information: http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm

US BOXED WARNINGS:
LEMTRADA (R):

CAMPATH (R):

CONTRAINDICATIONS:
LEMTRADA (R):
CAMPATH (R):


Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


General:

Monitoring:
CARDIOVASCULAR:
HEMATOLOGIC:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.